Abaris Investment Management AG recently announced the acquisition of new stake in Advent Technologies Holdings Inc (NASDAQ:ADN). The institutional investor has increased its shareholding in the Utilities company by 125.71% to 0.79 million shares with purchase of 0.44 million shares. This fresh investment now brings its stake to 1.26% valued currently at $0.29 million. In addition, Geode Capital Management LLC raised its holdings by 67206.0 to 0.39 million shares. And Morgan Stanley & Co. LLC has lifted its position by 203.61% or 0.14 million shares – to 0.21 million shares.
With over 9.74 million Advent Technologies Holdings Inc (ADN) shares trading Friday and a closing price of $0.21 on the day, the dollar volume was approximately $2.05 million. The shares have shown a negative half year performance of -63.96% and its price on 12/22/23 lost nearly -32.76%. Currently, there are 51.72M common shares owned by the public and among those 45.94M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 17 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 4,688 shares. Insider sales of the common stock occurred on 16 occasions, with total insider shares sold totaling 362,492 shares.
The top 3 mutual fund holders in Advent Technologies Holdings Inc are BNP Paribas Funds – Energy Transi, Vanguard Total Stock Market ETF, and Vanguard Extended Market Index Fu. BNP Paribas Funds – Energy Transi owns 4.46 million shares of the company’s stock, all valued at over $1.66 million. Vanguard Extended Market Index Fu now owns shares totaling to 0.81% of the shares outstanding.
Shares of Advent Technologies Holdings Inc (NASDAQ: ADN) opened at $0.1958, down -$0.11 from a prior closing price of $0.31. However, the script later moved the day high at 0.2200, down -32.76%. The company’s stock has a 5-day price change of -31.68% and -54.75% over the past three months. ADN shares are trading -88.30% year to date (YTD), with the 12-month market performance down to -88.49% lower. It has a 12-month low price of $0.29 and touched a high of $2.09 over the same period. ADN has an average intraday trading volume of 469.17K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -40.11%, -46.89%, and -68.70% respectively.
Institutional ownership of Advent Technologies Holdings Inc (NASDAQ: ADN) shares accounts for 12.60% of the company’s 51.72M shares outstanding. Mutual fund holders own 11.41%, while other institutional holders and individual stakeholders account for 23.65% and 1.19% respectively.
It has a market capitalization of $13.24M and a beta (3y monthly) value of 0.06. The earnings-per-share (ttm) stands at -$1.76. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.74% over the week and 8.79% over the month.
Analysts forecast that Advent Technologies Holdings Inc (ADN) will achieve an EPS of $Accenture plc for the current quarter, $354.45 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Astrazeneca PLC while analysts give the company a high EPS estimate of $Automatic Data Processing, Inc.. Comparatively, EPS for the current quarter was $Analog Devices, Inc. a year ago. Earnings per share for the fiscal year are expected to decrease by -14.70%, and 98.10% over the next financial year.
Looking at the support for the ADN, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on May 18, 2021, with the firm’s price target at $20.
